Scarica l'app Stockscreener
36.25
3.10%
1.09
Dopo l'orario di chiusura:
36.25
Precedente Chiudi:
$35.16
Aprire:
$35.25
Volume 24 ore:
24,007
Relative Volume:
1.03
Capitalizzazione di mercato:
$211.01M
Reddito:
-
Utile/perdita netta:
$-7.12M
Rapporto P/E:
-15.76
EPS:
-2.3
Flusso di cassa netto:
$-6.82M
1 W Prestazione:
+3.54%
1M Prestazione:
+12.89%
6M Prestazione:
+57.75%
1 anno Prestazione:
+5,054%
Intervallo 1D:
$34.91
$36.25
Intervallo di 1 settimana:
$31.84
$36.25
Portata 52W:
$0.3438
$54.30
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Nome
Monopar Therapeutics Inc
Settore
Industria
Telefono
(847) 388-0349
Indirizzo
1000 SKOKIE BLVD SUITE 350, WILMETTE
Confronta MNPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
36.25 | 211.01M | 0 | -7.12M | -6.82M | -2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-19 | Ripresa | Piper Sandler | Overweight |
| 2025-01-10 | Iniziato | Piper Sandler | Overweight |
| 2024-10-11 | Iniziato | Rodman & Renshaw | Buy |
| 2021-01-28 | Iniziato | ROTH Capital | Buy |
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know - MSN
Monopar Therapeutics (NASDAQ:MNPR) Trading 0.4% Higher – Time to Buy? - Defense World
Monopar Therapeutics Inc. and Excel Diagnostics and Nuclear Oncology Center Announce Expanded Access Program for Mnpr-101-Zr and Mnpr-101-Lu in Advanced Cancers - MarketScreener
Monopar and EDNOC Announce Expanded Access Program for MNPR-101- - GuruFocus
Monopar Therapeutics (MNPR) Gains FDA Nod for Expanded Access Program | MNPR Stock News - GuruFocus
Monopar Therapeutics Announces FDA Authorization for Expanded Access Program of Investigational Agents MNPR-101-Zr and MNPR-101-Lu in Collaboration with Excel Diagnostics - Nasdaq
FDA Greenlights Expanded Access: New Treatment Hope for Breast, Pancreatic, and Colorectal Cancer Patients - Stock Titan
Learn to Evaluate (MNPR) using the Charts - news.stocktradersdaily.com
Head to Head Contrast: Monopar Therapeutics (NASDAQ:MNPR) vs. Climb Bio (NASDAQ:CLYM) - Defense World
Monopar Therapeutics (MNPR) Gains Buy Rating and $71 Price Targe - GuruFocus
Monopar Therapeutics (MNPR) Gains Buy Rating and $71 Price Target | MNPR Stock News - GuruFocus
Monopar Therapeutics (MNPR) Set for Inclusion in Russell Indexes - GuruFocus
Monopar Therapeutics (MNPR) Set for Inclusion in Russell Indexes | MNPR Stock News - GuruFocus
Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - The Manila Times
Monopar joins Russell 3000 and 2000 indexes, growth acknowledged By Investing.com - Investing.com UK
Monopar Therapeutics Added to Russell Indexes, Gains Access to $10.6T Benchmark Assets - Stock Titan
Piper Sandler Reaffirms Their Buy Rating on Monopar Therapeutics Inc (MNPR) - The Globe and Mail
(MNPR) Trading Advice - news.stocktradersdaily.com
Research Analysts Offer Predictions for MNPR Q2 Earnings - Defense World
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock - The Globe and Mail
Monopar Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Monopar (MNPR) Projects Financial Stability Through 2026 | MNPR Stock News - GuruFocus
Monopar Therapeutics reports Q1 EPS (38c), consensus (57c) - TipRanks
Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments - The Manila Times
Monopar Therapeutics SEC 10-Q Report - TradingView
2,037 Shares in Monopar Therapeutics Inc. (NASDAQ:MNPR) Acquired by JPMorgan Chase & Co. - Defense World
(MNPR) Proactive Strategies - news.stocktradersdaily.com
Monopar Therapeutics (MNPR) Showcases ALXN1840's Efficacy for Wi - GuruFocus
Monopar Therapeutics Inc expected to post a loss of 68 cents a shareEarnings Preview - TradingView
Monopar Therapeutics Highlights ALXN1840 Data at EASL 2025 - TipRanks
Monopar Therapeutics (MNPR) Showcases ALXN1840's Efficacy for Wilson Disease | MNPR Stock News - GuruFocus
Monopar Therapeutics (MNPR) Expected to Announce Quarterly Earnings on Thursday - Defense World
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 | MNPR Stock News - GuruFocus
Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 - The Manila Times
Geode Capital Management LLC Acquires 24,530 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) - Defense World
Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025 - Insider Monkey
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 - The Manila Times
Why These 15 Healthcare Stocks Are Surging in 2025 - Insider Monkey
U.S. Severe Oral Mucositis Market Projected To Witness - openPR.com
(MNPR) Investment Analysis - news.stocktradersdaily.com
Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million. - marketscreener.com
(MNPR) Long Term Investment Analysis - news.stocktradersdaily.com
Major Shareholder Sells Big Chunk of Monopar Therapeutics Stock! - TipRanks
Monopar Therapeutics CEO Robinson sells $1.17 million in stock By Investing.com - Investing.com Canada
Jones Trading Reiterates “Hold” Rating for Monopar Therapeutics (NASDAQ:MNPR) - Defense World
HC Wainwright Issues Negative Forecast for MNPR Earnings - Defense World
What is HC Wainwright’s Forecast for MNPR FY2029 Earnings? - Defense World
Monopar Therapeutics downgraded to Hold from Buy at JonesResearch - TipRanks
We Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business Growth - Yahoo
Monopar Therapeutics Inc Azioni (MNPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):